Skip to main content

Table 1 Baseline patient characteristics

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Characteristic mFOLFIRINOX (n = 27) Gemox (n = 22) P value
Age
 Median, range 58 (41–73) 56.5 (36–75) 0.817
Sex    0.181
 Male 15 (55.6) 8 (36.4)  
 Female 12 (44.4) 14 (63.6)  
ECOG    0.407
 0 13 (48.1) 8 (36.4)  
 1 14 (51.9) 14 (63.6)  
Primary tumor sites    0.434
 Intrahepatic 16 (59.3) 9 (40.9)  
 Hilar 9 (33.3) 11 (50.0)  
 Distal 2 (7.4) 2 (9.1)  
Disease status    0.276
 Locally advanced 6 (22.2) 8 (36.4)  
 Metastatic 21 (77.8) 14 (63.6)  
Metastatic site
 Liver 17 (63.0) 13 (59.1) 0.782
 Lung 5 (18.5) 2 (9.1)
 Bone 1 (3.7) 0 (0)
 Other 1 (3.7) 1 (4.5)
CA19–9
 Median, range 172.0 (6.5–18,940) 151.3 (1.7–26,666) 0.680
  1. ECOG Eastern Cooperative Oncology Group
  2. Data are presented as n (%) for categorical variables and as median (range) for continuous variables